Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Robert A Burger,Wei Deng,Vicky Makker,Yvonne Collins,Heidi Gray,Robert Debernardo,Lainie P Martin,Carol Aghajanian

Gynecologic Oncology（2018）

引用 9|浏览17

暂无评分

摘要

•First ovarian cancer trial targeting the ALK1 receptor signal transduction pathway.•Phase II trial of dalantercept in patients with persistent or recurrent disease.•Insufficient efficacy to warrant further investigation.

查看译文

关键词

Dalantercept,Ovarian cancer,Clinical trial,Phase II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要